|
ZA201107039B
|
|
Transdermal pharmaceutical preparation and administration of tirofiban
|
|
EP2408440A1
|
|
Transdermal pharmaceutical preparation and administration of tirofiban
|
|
US2008139511A1
|
|
Combination Therapies Employing Ace Inhibitors and Uses Thereof for the Treatment of Diabetic Disorders
|
|
WO2008070995A1
|
|
Methods and treatments for prevention of acute renal failure following cardiac surgery
|
|
WO2008046202A1
|
|
USE OF PYπDOXAL-5'-PHOSPHATE FOR IMPROVING THE IMMUNE RESPONSE AND TREATMENT AND PREVENTION OF POST-OPERATIVE INFECTIONS
|
|
CA2590104A1
|
|
Method of reducing side effects of isoniazid
|
|
CA2590605A1
|
|
Improvement of mood, memory and cognitive function with pyridoxal 5'-phosphate
|
|
CA2590603A1
|
|
Treatment of tardive dyskinesia with pyridoxal 5'-phosphate
|
|
WO2007137409A1
|
|
Treatment and prevention of cognitive decline
|
|
WO2007121588A1
|
|
Treatment of atrial fibrillation
|
|
CA2632090A1
|
|
Selected dosage for the treatment of cardiovascular and related pathologies
|
|
AU2006220407A2
|
|
Treatment of cerebrovascular disease
|
|
US2009215727A1
|
|
Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds
|
|
CA2603334A1
|
|
Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
|
|
EP1790331A1
|
|
Use of pyridoxal-5-phosphate for the treatment of cardiovascular and related pathologies
|
|
EP1841436A1
|
|
Compounds and methods for regulating triglyceride levels
|
|
CN101111251A
|
|
Novel formulation of pyridoxal 5'-phosphate and method of preparation
|
|
WO2006056078A1
|
|
Novel formulation of pyridoxal 5'-phosphate and method of preparation
|
|
EP1853275A1
|
|
Formulations of pyridoxal -5'-phosphate and methods of preparation
|
|
CA2585165A1
|
|
Dual antiplatelet/anticoagulant pyridoxine analogs
|
